Colon Cancer in Young Adults: Why Rates Are Rising Under 50 and When Screening Should Start

The search spike this time did not come from a celebrity diagnosis. It came from a lab. In April 2025, a genomic study published in Nature reported that a bacterial toxin called colibactin leaves a distinctive fingerprint in tumor DNA, and that fingerprint turned up far more often in colorectal cancers diagnosed before age 40 than after 70. Within days, the phrase colon cancer in young adults was back at the top of health searches, tangled up with older headlines about millennials, sugary drinks, and a screening age that quietly dropped to 45.

As of mid-2025, the underlying numbers have not changed much since those headlines first appeared. They were already alarming enough. What has changed is how many people in their thirties are now asking a doctor a question their parents never had to ask at that age.

This piece sorts the settled facts from the plausible theories, grades the evidence honestly, and lays out exactly when screening should begin for whom.

What changed recently: the dates behind the headlines

Five dated events explain why this topic keeps resurfacing, and none of them is a rumor.

In 2018, the American Cancer Society became the first major U.S. body to recommend that average-risk adults start colorectal screening at 45 instead of 50. In May 2021, the U.S. Preventive Services Task Force, the independent panel whose grades shape most insurance coverage, followed with a grade B recommendation for ages 45 to 49. The CDC screening guidance now reflects that age.

In January 2024, the annual cancer statistics report noted that colorectal cancer had become the leading cause of cancer death in American men under 50 and the second leading cause in women under 50, behind breast cancer. In December 2024, a 50-country analysis in The Lancet Oncology found early-onset rates rising in 27 of them, including the United States, England, Australia, Canada, and several countries where colorectal cancer was historically uncommon.

Then came the April 2025 Nature paper on colibactin. Colibactin is a DNA-damaging toxin produced by certain strains of Escherichia coli that live in the gut. Its mutational signature, a pattern of DNA changes it leaves behind, appeared about 3.3 times more often in tumors from people diagnosed under 40 than in those diagnosed over 70, and the damage appeared to date to the first decade of life.

One more practical shift: in 2024 the FDA approved the first blood-based screening test for adults 45 and older at average risk. It is an option, not a replacement for colonoscopy, and a positive result still requires a colonoscopy to look for the cause.

Each of these facts is real. How they connect is where the honest uncertainty begins.

How much is colon cancer in young adults actually rising?

Two things are true at once. Rates are climbing steadily in people under 50, and colorectal cancer is still uncommon in that age group. Reporting that ignores either half misleads readers.

Incidence, meaning new diagnoses per 100,000 people each year, has risen roughly 1 to 2 percent annually in Americans under 50 since the mid-1990s. Over the same stretch, incidence in adults over 65 has fallen, largely because screening removes precancerous growths before they turn malignant. The result is a shift in who gets diagnosed: about 20 percent of colorectal cancers in 2019 occurred in people under 55, compared with 11 percent in 1995.

In absolute terms, the numbers remain modest. An American’s chance of being diagnosed with colorectal cancer before 50 is on the order of 1 in 300. Roughly 20,000 of the approximately 150,000 colorectal cancers diagnosed each year in the United States occur in people under 50. That is not a wave crashing over an entire generation; it is a persistent, measurable trend moving in the wrong direction.

Rectal cancer is rising faster than colon cancer in this age group, and tumors in younger patients cluster on the left side of the colon and in the rectum. Rates are increasing in both men and women and across racial and ethnic groups, though Black Americans and Alaska Native people carry higher overall colorectal cancer burdens at every age.

The pattern is not a screening artifact. Adults under 45 have never been routinely screened, so more cases cannot be explained by more looking. Something in the population is genuinely different.

Can someone in their 20s get colon cancer?

Yes, though it is rare, and the profile of a 26-year-old’s colon cancer often differs from a 46-year-old’s.

Incidence in Americans aged 20 to 29 is in the range of 2 to 3 cases per 100,000 people per year. For comparison, incidence in people in their seventies is well above 100 per 100,000. A percentage increase from a very small base can sound dramatic while still translating to a small number of people; that is exactly what has happened in the youngest adults, where rates have roughly doubled over three decades but remain low.

What sets this group apart is genetics. Among all colorectal cancers, about 3 percent are caused by an inherited syndrome. Among people diagnosed before 50, studies using broad genetic testing have found an inherited cancer-predisposing variant in roughly 1 in 5 to 1 in 6 patients, and the proportion climbs the younger the patient. That means a diagnosis in one’s twenties is far more likely to have a family thread running through it, even when no relative was ever diagnosed, because the variant may have been silent or the family small.

It also means genetic counseling is standard of care after an early diagnosis. A genetic counselor is a health professional trained to interpret inherited risk and explain testing options. Their findings can change screening plans for siblings, children, and parents.

The remaining four in five early cases, however, have no identifiable inherited cause. Those are the cases driving the population trend, and they are the ones researchers are still working to explain.

Why are so many young adults getting colorectal cancer? The birth cohort clue

Epidemiologists use the phrase birth cohort effect to describe a risk that tracks with the year a person was born rather than with their current age. Colorectal cancer in young adults shows a textbook example.

A 2017 analysis of U.S. registry data found that a person born around 1990 had about twice the risk of colon cancer and about four times the risk of rectal cancer as a person born around 1950, at the same age. Successive generations are carrying more risk with them as they age, which suggests the relevant exposures happened early, in childhood, adolescence, or even before birth.

That framing narrows the suspect list. Whatever changed must have changed for people born from roughly the 1960s onward, must have spread across many high-income countries in similar decades, and must plausibly act on the colon over a span of years. Childhood obesity rates, dietary patterns, antibiotic use, sedentary time, and shifts in the gut microbiome all fit that description. A single new chemical introduced last decade does not.

The global picture supports this reading. Countries that adopted Western-style diets and lifestyles earlier show earlier rises in young-onset cases; countries adopting them later are now showing the same curve, delayed. That consistency across borders is one of the stronger arguments that lifestyle and environment, rather than local quirks in healthcare, are driving the trend.

None of this identifies the cause. It does tell researchers where to look, and where not to.

What the evidence actually says about the causes

Grading matters here because most of what circulates online skips it. Evidence on cancer causes comes in three tiers: randomized controlled trials, which assign people to different exposures and are the gold standard; observational studies, which follow people and look for associations; and expert opinion, which fills gaps when data are thin.

Randomized trials on causes of early-onset colorectal cancer essentially do not exist. You cannot ethically assign children to decades of a particular diet. Every causal claim you read is therefore observational or mechanistic, which means it can show that two things travel together, not that one produces the other.

Within observational data, some associations are consistent and biologically plausible. Excess body weight is the most replicated: in a large cohort of U.S. nurses, women with obesity had roughly double the risk of colorectal cancer before 50 compared with women at a lower weight. Higher intake of sugar-sweetened beverages in adolescence and adulthood, low fiber intake, heavy alcohol use, smoking, and a Western-style dietary pattern heavy in processed meat and refined grains have each been linked to early-onset disease in cohort studies. Physical inactivity and prolonged sitting show similar associations.

Weaker, hypothesis-stage evidence surrounds antibiotic exposure in childhood, ultra-processed food, and disruption of the gut microbiome, the community of bacteria living in the intestine. These ideas are reasonable and under active study; they are not established.

Crucially, obesity and diet trends do not fully account for the rise. Many young patients are lean, active, and eat well. The honest summary is that lifestyle explains part of the trend, and a substantial part remains unexplained.

Does the gut microbiome explain colon cancer under 50?

The colibactin story deserves a careful telling, because it is the most exciting lead in years and also the most easily overstated.

Certain strains of E. coli carry a cluster of genes called pks that lets them make colibactin. Colibactin damages the DNA of colon cells in a characteristic way, leaving behind what geneticists call a mutational signature, a fingerprint of specific changes scattered through the genome. The April 2025 Nature analysis of nearly 1,000 colorectal tumors from 11 countries found this fingerprint about 3.3 times more often in cancers diagnosed before 40 than after 70. By estimating when the mutations arose, the authors concluded that the damage likely occurred in the first ten years of life.

That is a striking observation. It fits the birth cohort pattern, it fits the early-exposure hypothesis, and it offers a mechanism. It is also correlational. The study shows that the fingerprint is more common in young-onset tumors; it does not prove colibactin caused those tumors, nor does it explain why children born after the 1960s might carry more of these bacteria. Roughly 20 to 40 percent of healthy adults harbor pks-positive E. coli, so carriage alone is clearly not sufficient.

Other microbes are under scrutiny too, notably Fusobacterium nucleatum, which is enriched in many colorectal tumors. The field is also examining how antibiotics, cesarean birth, infant feeding, and diet shape a child’s microbiome.

What this does not justify: buying a consumer microbiome test, taking probiotics to prevent cancer, or seeking antibiotics to clear a bacterium. No trial supports any of those steps, and the researchers themselves have said so.

Family history and Lynch syndrome: who is at highest risk

Before any discussion of screening age, one group needs to be pulled out of the crowd, because the general rules do not apply to them.

A first-degree relative is a parent, sibling, or child. Having one first-degree relative with colorectal cancer roughly doubles a person’s own lifetime risk; two relatives, or one diagnosed before 50, raise it further. Adenomas, the precancerous polyps found at colonoscopy, count as well: a parent who had an advanced adenoma removed shifts a family’s risk profile even if no cancer ever developed.

Lynch syndrome is the most common inherited cause. It is a condition in which a person is born with a faulty copy of one of several DNA repair genes, so errors accumulate faster in colon cells. Lynch syndrome affects roughly 1 in 280 people, most of whom do not know they have it, and it carries a lifetime colorectal cancer risk of up to 50 to 80 percent depending on the gene. Diagnoses in the thirties and forties are typical. Familial adenomatous polyposis, a rarer syndrome causing hundreds of polyps, produces cancers even earlier.

Inflammatory bowel disease, meaning long-standing ulcerative colitis or Crohn’s disease of the colon, also raises risk, with surveillance colonoscopies typically beginning about eight years after diagnosis. A personal history of radiation to the abdomen or pelvis in childhood does the same.

The practical point is simple. Anyone with a relative diagnosed with colorectal cancer or advanced polyps should raise it with a clinician now, not at 45. Knowing the relative’s age at diagnosis is often the single most useful piece of information to bring.

Why colon cancer under 50 is often found later

Younger patients are more likely than older patients to be diagnosed with stage III or IV disease, the stages at which cancer has spread to lymph nodes or to distant organs. Several studies put the share of advanced-stage diagnoses in young adults near 60 percent. This is not because their tumors are inherently more aggressive, though some are; it is mostly a story about timing.

Nobody under 45 is invited for routine screening, so the safety net that catches silent polyps in a 60-year-old simply does not exist for a 35-year-old. A cancer has to announce itself before anyone looks.

When it does announce itself, the announcement is frequently misread. Bleeding in a healthy 32-year-old is, statistically, far more likely to be hemorrhoids than cancer, and clinicians reason accordingly. Iron deficiency in a young woman is commonly attributed to menstruation. Abdominal pain and changed bowel habits are attributed to irritable bowel syndrome or stress. Each of those explanations is usually correct, which is precisely why the uncommon case slips through.

A 2024 analysis of U.S. insurance records quantified the cost of that pattern. Among people later diagnosed with early-onset colorectal cancer, several warning signs had appeared in medical records between three months and two years before diagnosis, and those with multiple documented signs had markedly higher odds of disease. Other studies have reported diagnostic delays of several months in young patients compared with older ones.

The lesson for readers is not to fear every symptom. It is that persistence matters, and that returning to a clinician when something does not resolve is reasonable, not overreacting.

Colonoscopy age 45: when screening should start and for whom

A colonoscopy is an examination in which a physician passes a flexible camera through the entire colon, usually under sedation, and removes any polyps found along the way. Screening means testing people who have no symptoms, and the age at which it begins is set by weighing how common cancer is against the small risks and effort of testing.

For adults at average risk, both the U.S. Preventive Services Task Force and the American Cancer Society now say screening should start at 45. The change from 50 was driven directly by the rising incidence in people in their forties, whose risk now resembles that of 50-year-olds two decades ago. Screening continues through 75; between 76 and 85 the decision is individualized.

Uptake has lagged the guideline. Only about one in five Americans aged 45 to 49 is up to date, compared with roughly two in three adults over 50. That gap represents the most immediately fixable problem in this entire topic.

Your situation	Suggested screening start	Notes
No family history, no bowel disease, no symptoms	Age 45	Any recommended test; choose one you will complete
One first-degree relative with colorectal cancer or advanced polyp	Age 40, or 10 years before that relative’s diagnosis age, whichever is earlier	Colonoscopy usually preferred, often every 5 years
Lynch syndrome confirmed or suspected	Typically 20 to 25	Colonoscopy every 1 to 2 years; genetics referral
Ulcerative colitis or Crohn’s colitis	About 8 years after diagnosis	Surveillance schedule set by gastroenterologist
Any symptoms, at any age	Now	This is evaluation, not screening

The table reflects U.S. guideline consensus; the right plan for any individual is set by their clinician.

Colonoscopy vs stool tests: which screening option fits a 45-year-old?

Gastroenterologists like to say the best screening test is the one that actually gets done. The evidence behind that line is stronger than the slogan suggests.

Several tests are endorsed for average-risk adults. Colonoscopy, done every 10 years if normal, is the only test that both finds and removes polyps in the same visit. The fecal immunochemical test, or FIT, is a home kit that detects tiny amounts of blood in stool and is repeated every year. A multitarget stool DNA test looks for both blood and altered DNA shed by tumors, repeated every one to three years. CT colonography images the colon with a scanner every five years. Flexible sigmoidoscopy examines only the lower colon, every five years. The blood-based test approved in 2024 detects tumor DNA in a blood sample; it is less sensitive for precancerous polyps and is repeated every three years.

How strong is the evidence? Flexible sigmoidoscopy and older stool tests have randomized trial data showing reduced colorectal cancer deaths. Colonoscopy’s randomized evidence arrived in 2022 with a large European trial: an 18 percent reduction in colorectal cancer incidence when everyone invited was counted, and roughly 31 percent when only those who actually attended were analyzed. Observational studies suggest larger benefits. Stool DNA and blood tests are supported by accuracy studies rather than outcome trials.

Two rules govern every option. A positive result on any non-colonoscopy test must be followed by a colonoscopy; a positive stool test that is never followed up provides no protection. And a test with symptoms present is not screening; it is diagnosis, and it should not wait for a guideline age.

What young adults can do now to lower their risk

Prevention advice for early-onset colorectal cancer rests on the same observational foundation as the cause research, so it is worth being candid: these steps are associated with lower risk, and they are unambiguously good for cardiovascular and metabolic health, but no trial has proven they prevent colon cancer specifically in someone under 50.

Body weight has the most consistent data. Maintaining a weight in the healthy range through adulthood is associated with lower colorectal cancer risk at every age, and the association appears stronger for early-onset disease. Physical activity acts partly through weight and partly independently; adults meeting the standard target of about 150 minutes of moderate activity a week show roughly 20 to 25 percent lower colorectal cancer risk in pooled cohorts.

Diet evidence points in familiar directions. Higher intake of whole grains, fiber, and dairy is associated with lower risk; the World Cancer Research Fund rates these as probable protective factors. Processed meat is classified by the World Health Organization’s cancer agency as a Group 1 carcinogen for colorectal cancer, meaning the evidence for a causal link is considered sufficient, though the absolute increase per serving is modest. Red meat is rated probably carcinogenic. Alcohol raises risk in a dose-dependent way, and tobacco smoking does the same.

Sugar-sweetened drinks deserve a specific mention because of the early-onset data: in one cohort, women who drank two or more servings a day in adulthood had about double the risk of colorectal cancer before 50, and each daily serving in adolescence was associated with higher risk. That is one study, observational, but it is consistent with the broader picture.

Supplements have not earned a place on this list. Vitamin D, folate, and antioxidant trials have not shown reliable protection.

How treatable is early-stage colon cancer?

Stage describes how far a cancer has spread. Stage I is confined to the inner layers of the bowel wall; stage II has grown through the wall; stage III involves nearby lymph nodes; stage IV has spread to distant organs such as the liver or lungs.

The gap in outcomes across those stages is the entire argument for screening. Using U.S. registry data, the five-year relative survival rate, meaning the proportion of patients alive five years after diagnosis compared with people of the same age without cancer, is about 91 percent for colorectal cancer that is still localized, about 73 percent when it has reached regional lymph nodes, and about 13 to 15 percent when it has spread to distant sites. These are population averages from observational registries, not predictions for any individual, and they lag several years behind current treatment.

Early-stage disease is usually treated with surgery alone. Stage III typically adds chemotherapy. Stage IV is managed with combinations of chemotherapy, targeted drugs matched to the tumor’s genetic features, immunotherapy for the subset with certain DNA repair defects, and surgery when spread is limited. Younger patients generally tolerate intensive treatment well, yet studies comparing outcomes stage-for-stage have not shown that youth itself improves them.

One fact belongs in every article on this subject: most colorectal cancers begin as a polyp that takes roughly 10 years to become malignant. A polyp snipped out during a screening colonoscopy never gets that chance. That is why screening can lower incidence, not just find cancers earlier, and why the stage-at-diagnosis numbers above are, for screened populations, largely avoidable.

Common myths about bowel cancer in young adults

Viral posts about this topic tend to recycle the same handful of errors. Here are the ones most worth correcting.

Myth: Only older people get colon cancer. Roughly one in eight colorectal cancers in the United States is now diagnosed before 50. It remains more common in older adults, but age alone no longer rules it out, which is precisely why the screening age moved.

Myth: With no family history, there is nothing to worry about. About four in five young-onset cases occur in people with no known inherited syndrome, and many have no affected relatives at all. Family history raises risk; its absence does not remove it.

Myth: A single modern culprit explains the rise. Social media has nominated seed oils, plastics, and various other villains. No study has linked any one of these to early-onset colorectal cancer. The evidence points to a mix of weight, diet, activity, and microbiome factors acting over decades, with a large share still unexplained.

Myth: The microbiome findings mean a probiotic or a microbiome test can prevent it. The colibactin research is a promising lead about mechanism. No product, test, or antibiotic course has been shown to lower colorectal cancer risk, and none is recommended for that purpose.

Myth: Stool tests are second-rate. Annual FIT is endorsed alongside colonoscopy by every major U.S. guideline and has randomized trial support for reducing deaths. Its weakness is not accuracy; it is people skipping the follow-up colonoscopy after a positive result.

Myth: Colonoscopy is dangerous. Serious complications such as bleeding or perforation occur in roughly 1 to 3 per 1,000 procedures, most often when polyps are removed, and are usually manageable. Sedation means most people remember little of it.

When to see a doctor

This article has deliberately avoided a symptom checklist, because self-diagnosis is not the goal. The goal is knowing when a conversation with a clinician is warranted. In a young adult, each of the changes below is far more likely to have a benign cause than a cancerous one, and a clinician’s job is to sort that out with a proper history, examination, and, when needed, tests.

Make an appointment, at any age, if any of the following persists for more than a few weeks or keeps returning:

• Blood in or on the stool, or bleeding from the rectum, even if hemorrhoids seem the obvious explanation
• A lasting change in bowel habits, such as new diarrhea, constipation, or narrower stools
• Ongoing abdominal pain, cramping, or bloating that does not settle
• Unexplained weight loss or unexplained fatigue
• A diagnosis of iron deficiency anemia without a clear cause
• A feeling that the bowel does not empty completely

Seek urgent care the same day for heavy rectal bleeding, black tarry stools, severe abdominal pain, or vomiting with an inability to pass stool, since these can signal bleeding or obstruction from many causes.

Bring specifics: how long the change has lasted, any relatives with colorectal cancer or polyps and their ages at diagnosis, and any personal history of inflammatory bowel disease. Ask directly whether a colonoscopy or stool test is appropriate, and if a first explanation does not lead to improvement, go back. Every decision about testing, referral, and follow-up belongs to the clinician who knows your history; the purpose of understanding this trend is simply to make sure that conversation happens early enough to matter.

Frequently asked questions

Can someone in their 20s get colon cancer?

Yes, although it remains rare, at roughly 2 to 3 cases per 100,000 people per year in this age group. Diagnoses this young are more likely to involve an inherited syndrome such as Lynch syndrome, so genetic counseling is standard afterward. Anyone in their twenties with persistent bowel changes or bleeding should see a clinician rather than assume age rules it out.

Why are so many young adults getting colon cancer?

No single cause has been proven. Observational studies consistently link early-onset colorectal cancer to excess body weight, sugary drinks, low-fiber Western diets, alcohol, and inactivity, while newer research implicates gut bacteria that produce a DNA-damaging toxin called colibactin, likely acting in childhood. Together these explain part of the rise; a substantial portion remains unexplained and under active study.

What are signs of colon cancer in young adults?

Rectal bleeding, a lasting change in bowel habits, ongoing abdominal pain, and unexplained iron deficiency anemia are the changes most often documented before an early-onset diagnosis. Each is far more commonly caused by benign conditions, so they are reasons to book a clinician visit and ask about testing, not tools for self-diagnosis. Persistence beyond a few weeks is the key signal to act on.

How treatable is early stage colon cancer?

Registry data show a five-year relative survival rate of about 91 percent for colorectal cancer that is still localized to the bowel, compared with roughly 13 to 15 percent for cancer that has spread to distant organs. Early-stage disease is usually managed with surgery alone. These are population averages, not individual predictions, and treatment plans are set by the oncology team.

Is colorectal cancer in young adults a different disease from the one older people get?

Mostly no. Tumors in younger patients more often sit in the left colon and rectum, and a larger share carries inherited variants, but the biology and treatment are broadly similar stage for stage. The bigger difference is timing: younger people are diagnosed at later stages because they are not screened and early signs are often attributed to benign causes.

Why is colon cancer under 50 rising while rates in older adults fall?

Screening explains the fall in older adults, since colonoscopy removes precancerous polyps before they become cancer. Adults under 45 are not routinely screened, so that protective effect does not reach them, and generations born after the 1960s appear to carry more risk from early-life exposures. The opposite trends are two sides of the same story: prevention working where it is applied.

Is colonoscopy at age 45 really necessary if I feel fine?

Feeling fine is the point; screening is designed for people without symptoms, because early polyps and cancers produce none. Both the U.S. Preventive Services Task Force and the American Cancer Society recommend starting at 45 for average-risk adults. Colonoscopy is one option among several, including annual stool tests, and a clinician can help choose the one you are most likely to complete.

Should I ask for a colonoscopy before 45 if a parent had colon cancer?

Yes, raise it now. With one first-degree relative diagnosed with colorectal cancer or an advanced polyp, U.S. guidelines suggest starting colonoscopy at 40 or ten years before that relative’s age at diagnosis, whichever comes first, and repeating it more often than the standard ten years. Bring the relative’s diagnosis age to the appointment; your clinician will set the plan.

Do the new findings about gut bacteria mean I should take probiotics to prevent bowel cancer in young adults?

No. The 2025 research linking colibactin-producing E. coli to early-onset tumors is a promising lead about how the disease might begin, not a proven cause, and no probiotic, microbiome test, or antibiotic course has been shown to lower colorectal cancer risk. The researchers themselves have cautioned against acting on the finding. Established prevention still centers on weight, activity, diet, and timely screening.

Does a normal stool test mean I do not need a colonoscopy?

If the stool test is negative and you have no symptoms, you generally do not need a colonoscopy until the next scheduled test, yearly for FIT or every one to three years for stool DNA tests. A positive result, however, always requires a follow-up colonoscopy; skipping that step erases the benefit. Symptoms at any age call for evaluation regardless of a prior negative result.

References

• CDC – Screening for Colorectal Cancer
• Cleveland Clinic – Colorectal (Colon) Cancer
• NHS – Bowel cancer
• MedlinePlus – Colorectal Cancer

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.